^
    1d
    CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screen. (PubMed, NPJ Breast Cancer)
    Early clinical data demonstrated activity of BLU-222, a potent and selective CDK2 inhibitor, both as monotherapy (CCNE1 amplified) and in combination with ribociclib and fulvestrant in patients with HR+/HER2- breast cancer. These findings provide evidence that CDK2i combined with CDK4/6i can address multiple known mechanisms of resistance to CDK4/6i, enhancing antitumor responses in preclinical breast cancer models.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1)
    |
    HR positive • HER-2 negative
    |
    Kisqali (ribociclib) • fulvestrant • cirtociclib (BLU-222)
    1d
    Premenopausal Patients With Clinically Aggressive Metastatic Breast Cancer Successfully Treated With a First-Line Palbociclib-Containing Regimen: Two Cases and Literature Review. (PubMed, Cancer Rep (Hoboken))
    In the two cases we reported, first-line palbociclib therapy shows adequate and timely responses for premenopausal HR+/HER2- metastatic breast cancer patients. Although not widely utilized, frontline therapy with palbociclib combined with endocrine treatments may be a choice for HR+/HER2- metastatic breast cancer patients experiencing severe visceral metastasis.
    Review • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Ibrance (palbociclib)
    1d
    Less endocrine therapy in HR+/HER2- breast cancer: a nationwide trend despite unchanged guidelines. (PubMed, Breast)
    Despite unchanged guideline recommendations, fewer patients started ET over time. This trend, and regional variation, suggests that a more reticent approach by physicians to initiating ET for HR+/HER2- breast cancer may be contributing to it.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    1d
    Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Novartis Pharmaceuticals
    New P1 trial
    1d
    VSV-02 Compassionate Use in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=6, Recruiting, The First Affiliated Hospital of Xinxiang Medical College
    New P1 trial
    1d
    Imlunestrant: First Approval. (PubMed, Drugs)
    In September 2025, imlunestrant was approved for the treatment of adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy in the USA. This article summarizes the milestones in the development of imlunestrant leading to this first approval for use in patients with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • HER-2 mutation • ESR1 mutation
    |
    Inluriyo (imlunestrant)
    2d
    Evaluating Ki-67 and PR as prognostic indicators in CDK4/6 inhibitor treatment for metastatic breast cancer. (PubMed, Ecancermedicalscience)
    Patients with PR values <20% tended to have shorter PFS, unlike the Ki-67 value, which did not demonstrate an impact on PFS. This suggests a prognostic value of PR expression levels in this scenario.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    2d
    Molecular subtype-driven disparities in intraoperative touch imprint cytology accuracy for sentinel lymph node assessment in clinically node-positive breast cancer treated with neoadjuvant chemotherapy. (PubMed, Eur J Med Res)
    Collectively, our study demonstrates that ITPC exhibits a robust accuracy for detecting SLN metastases in cN + breast cancer patients treated with NAC. The findings support the implementation of molecular subtype-specific SLN management: ITPC alone may be adequate for HER2-positive and TNBC tumors; for hormone receptor-positive (Luminal) subtypes, ITPC may need to be combined with molecular/immunohistochemical analysis.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative
    2d
    OPERA-02: Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer (clinicaltrials.gov)
    P3, N=1000, Recruiting, Olema Pharmaceuticals, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Kisqali (ribociclib) • letrozole • palazestrant (OP-1250)
    2d
    OASIS: Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers (clinicaltrials.gov)
    P2, N=400, Recruiting, UNICANCER
    New P2 trial
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    2d
    Lucentis Plus Tagolimumab in PD-L1+, HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors (clinicaltrials.gov)
    P2, N=35, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Lucentis (ranibizumab) • Simponi (golimumab)
    2d
    Impact of adverse events on survival outcomes in patients treated with CDK4/6 inhibitors for advanced breast cancer. (PubMed, Cancer Chemother Pharmacol)
    CDK4/6 inhibitors have distinct toxicity profiles. Effective AE management and dose adjustments are crucial for maintaining efficacy, emphasizing the need for AE prediction models to optimize CDK4/6i use in HR + HER2 - aBC.
    Journal • Adverse events
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)